Study Reference No. - C2D01121

Demographic Gender Age Location Compensation
History of perennial allergic rhinitis (nasal symptoms) to house dust mite for more than 1 year; non-smokers or smokers who are able to refrain from smoking for 6 hours prior to and during each EEC visits. Males and Females 18-65 Mississauga, ON $2,460
Study Details

Study Purpose

The primary purpose of this study is to compare the effectiveness of Altamira Medica’s AM-301 device (marketed in Europe as Bentrio) between treated and non-treated study participants in the treatment of Perennial Allergic Rhinitis (PAR).

Study Duration

5 clinic visits and a follow-up telephone call over approximately 65 days.

Study Schedule

General Screening


Medical Screening

Mulitiple dates starting 10-November-2021. Contact Recruitment.

Study Visit(s)

Multiple cohort dates starting 29-Nov-2021. Contact Recruitment.

Follow-Up Visit(s)


Other Notes

Bring Valid Photo ID.

COVID-19 test will be conducted prior to designated visits.